Expanded Access for Anti-IL8

Expanded access No longer available Bristol-Myers Squibb

This is an expanded access designed to provide access to Anti-IL8 for eligible participants.

Evaluation	Drug	Modality	Dose	Route
Background	ADAKITUG	Monoclonal antibody	—	—

No indication recorded.